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Abstract
Background: A Stanford University study reported that in asymptomatic GERD patients who
were being treated with a proton pump inhibitor (PPI), 50% had pathologic esophageal acid
exposure.
Aim: We considered the possibility that the high prevalence of pathologic esophageal reflux might
simply have resulted from calculating acidity as time pH < 4.
Methods: We calculated integrated acidity and time pH < 4 from the 49 recordings of 24-hour
gastric and esophageal pH from the Stanford study as well as from another study of 57 GERD
subjects, 26 of whom were treated for 8 days with 20 mg omeprazole or 20 mg rabeprazole in a
2-way crossover fashion.
Results: The prevalence of pathologic 24-hour esophageal reflux in both studies was significantly
higher when measured as time pH < 4 than when measured as integrated acidity. This difference
was entirely attributable to a difference between the two measures during the nocturnal period.
Nocturnal gastric acid breakthrough was not a useful predictor of pathologic nocturnal esophageal
reflux.
Conclusion:  In GERD subjects treated with a PPI, measuring time esophageal pH < 4 will
significantly overestimate the prevalence of pathologic esophageal acid exposure over 24 hours and
during the nocturnal period.
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Background
In 2004, a group from Stanford University reported that in
asymptomatic GERD patients who were being treated
with a PPI, 50% had pathologic esophageal acid exposure
[1]. The authors of this paper stated that they were sur-
prised by this high prevalence of pathologic esophageal
acid exposure and an accompanying editorial pointed out
that the findings were difficult to reconcile with a large
body of evidence supporting the outstanding therapeutic
efficacy of PPIs in GERD [2].
Previously [3], some of the present authors had reported
that measuring time esophageal pH < 4 underestimates
the effect of a PPI on esophageal acid exposure compared
to measuring esophageal acid exposure as integrated
esophageal acidity. We considered the possibility that the
high prevalence of pathologic esophageal reflux in the
Stanford study might simply have resulted from calculat-
ing acidity as time pH < 4. As a result, one of the present
authors (JDG) contacted one of the authors from Stanford
(GT) and proposed a collaboration that would involve
calculating both integrated acidity and time pH < 4 from
the original pH records. The present paper reports the
results of these analyses as well as analyses of results from
another study of GERD subjects that were conducted to
test hypotheses that were generated from the Stanford
data.
In analyses of both studies we found that calculating time
esophageal pH < 4 substantially overestimates the preva-
lence of pathologic esophageal reflux compared to that
determined by calculating integrated esophageal acidity.
This difference, in turn, resulted from time pH < 4 overes-
timating the prevalence of pathologic nocturnal esopha-
geal acidity.
We wondered if the overestimation of the prevalence of
pathologic esophageal reflux might affect the apparent
relationship between gastric acidity and pathologic
esophageal reflux observed in the original Stanford report
[1]. Accordingly, we examined relationships between gas-
tric acidity and pathologic esophageal reflux in the origi-
nal Stanford study and in another study of GERD subjects
treated with a PPI using both time gastric pH < 4 and inte-
grated gastric acidity.
Methods
This report is based on data from 3 separate studies that
have been described in detail previously [1,4].
The Stanford study (index study) involved 49 sympto-
matic GERD subjects who were treated with a PPI until
they were asymptomatic. At the end of this period, gastric
pH and esophageal pH were recorded continuously for 24
hours. The details of this study including a description of
the pH recordings have been reported previously [1]. In
the present analyses, 3 records were omitted because of
technical inadequacies. Data from this study were used to
compare the prevalence of pathologic esophageal reflux
defined using time pH < 4 and to that defined using inte-
grated acidity.
The 2nd study involved 26 healthy adults with no history
of gastrointestinal disease or symptoms [4]. In these sub-
jects, 24-hour gastric pH and esophageal pH were meas-
ured on 2 separate occasions, 7 days apart.
The 3rd study involved 57 adults with a history of GERD
who experienced heartburn at least 4 times per week for at
least 6 months [4]. In these subjects, 24-hour gastric pH
and esophageal pH were measured once. Data from the
second and third studies were used to establish cut-points
that define pathologic esophageal reflux measured as time
pH < 4 and as integrated acidity. These cut-points were
then used to define pathologic esophageal reflux in the
index study.
Also, in the 3rd study, 26 GERD subjects with esophageal
pH < 4 for at least 10% of the 24-hour baseline recording
period were randomized to receive 8 consecutive daily
doses of 20 mg omeprazole or 20 mg rabeprazole in a
crossover fashion with a 14-day washout between treat-
ment periods. Gastric pH and esophageal pH were meas-
ured for 24 hours on days 1, 2 and 8 with each treatment.
Analyses of data from Day 8 in the 3rd study were used to
attempt to confirm results from the index study that com-
pared pathologic esophageal reflux defined by time pH <
4 to that defined by integrated acidity.
For all pH recordings, subjects fasted from approximately
22:00 the evening before until the beginning of pH
recording the following morning at 8:00. Gastric pH and
esophageal pH values were recorded every 4 seconds using
an ambulatory, dual channel pH recording system
(Medtronic Synectics) with antimony electrodes
(Zinetics24 single-use, internal-standard pH catheter).
One electrode was placed in the esophagus 5 cm above
the manometrically defined upper border of the lower
esophageal sphincter. The other electrode was placed in
the stomach 10 cm below the manometrically defined
upper border of the lower esophageal sphincter (second
and third studies) or 5 cm below the diaphragm deter-
mined by chest radiograph (index study). Electrodes were
calibrated to pH 1 and 7, and connected to a portable data
storage unit (Digitrapper, Medtronic Synectics). Record-
ings began at 8:00 and continued for 24 hours. Data were
transferred from the portable data storage unit and proc-
essed using software designed for pH recordings (Poly-
gram for Windows, Version 2.04, Medtronic Synectics).BMC Gastroenterology 2008, 8:15 http://www.biomedcentral.com/1471-230X/8/15
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Raw data were exported from this software and used to
calculate integrated acidity and time pH < 4.
Recently, Medtronic notified customers that new temper-
ature correction factors should be used for the Slimline
pH catheter as well as for the Zinetics24 single-use, inter-
nal-standard pH catheter [5]. Subsequently, two studies
demonstrated the impact of these new correction factors
on measures of acidity calculated from pH recordings
[5,6]. We have not rescaled the data for the present analy-
ses so that readers will be able to compare the present
results to those from previous analyses of these same data
[1,4,7].
Gastric and esophageal pH were recorded every 4th second
for 24 hours. Integrated esophageal acidity was calculated
as described previously [3]. Integrated acidity is the time-
weighted average of the hydrogen ion concentration
expressed as mmol/L. It is also equal to the area under the
hydrogen ion concentration-time curve. In contrast to
time esophageal pH < 4, integrated esophageal acidity
fully quantifies esophageal acid exposure. For example,
two different one-hour periods of esophageal pH of 1 and
3 will give identical values for time esophageal pH < 4. In
contrast, integrated esophageal acidity calculated from
one hour of pH 1 will be 100-times higher than that cal-
culated from one hour of pH 3.
The 24-hour recordings were divided into postprandial
(9:00–22:00) and nocturnal (22:00–9:00) periods. As
reported previously [4], the duration of the postprandial
period was selected as 9:00–22:00, because integrated gas-
tric acidity over this period gave the optimal correlation
with meal-stimulated gastric acid secretion.
Bayes' rule was used to calculate the posterior probability
that the prevalence of pathologic esophageal reflux repre-
sented false positive values [8].
Posterior Probability = Prior Probability × Likelihood/
Total Probability
The likelihood value is the probability of the data for a
given proportion and was calculated for values of propor-
tions from 0 to 1.0 in steps of 0.05 using the following
equation.
Likelihood = (proportion)a × (1-proportion)b
where a is the number of subjects with pathologic esopha-
geal reflux and b is the number of subjects without path-
ologic esophageal reflux.
The total probability is the weighted average of the various
conditional probabilities calculated as
Total Probability = SUM [(Prior Probability)i × (Likeli-
hood)i]
Where (Prior Probability)I is the ith prior probability and
(Likelihood)I is the corresponding ith likelihood.
By dividing by total probability, all posterior probabilities
are adjusted so that they sum to 1.0.
Statistical analyses were performed using GraphPad for
InStat version 3.01 for Windows software.
Results
Previously [7], we used data from the 2nd and 3rd studies
to establish cut-points for 24-hour integrated esophageal
acidity and time esophageal pH < 4 that had optimal sen-
sitivity and specificity for distinguishing between normal
and GERD subjects. In the present analyses we used these
cut-points (8.1 mmol.hr/L for integrated acidity and 4.3%
for time pH < 4) to compare the prevalence of pathologic
esophageal reflux defined by the different measures of
esophageal acidity in the index study.
Figure 1-left illustrates that the prevalence of pathologic
24-hour esophageal reflux in the index study was signifi-
cantly higher (P = 0.0005, McNemar's Test) when meas-
ured as time pH < 4 than when measured as integrated
acidity. Figure 1-right shows that 14 normal values of inte-
grated acidity had corresponding values of pathologic
time pH < 4 as high as 14%.
We were interested in examining whether the differences
in prevalence of pathologic 24-hour esophageal acidity
occurred during the postprandial period, the nocturnal
period or both. Before we could compare integrated
esophageal acidity and time pH < 4 during the postpran-
dial and nocturnal periods, it was necessary to determine
cut-points that define pathologic esophageal reflux during
the postprandial and nocturnal periods. We are unaware
of any published values for integrated esophageal acidity
that define pathologic postprandial or nocturnal esopha-
geal reflux. Values for time esophageal pH < 4 that define
pathologic postprandial and nocturnal esophageal acid
exposure have been published [9-14]; however, we
wanted to determine cut-points for the 2 different meas-
ures of acidity using the same cohorts of subjects and the
same criterion. We determined these cut-points using
receiver operating characteristic (ROC) analyses of data
from the 2nd and 3rd studies, and selected the values for
postprandial and nocturnal integrated esophageal acidity
and time esophageal pH < 4 that had optimal sensitivity
and specificity for distinguishing between normal and
GERD subjects (Table 1).BMC Gastroenterology 2008, 8:15 http://www.biomedcentral.com/1471-230X/8/15
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Table 1 summarizes the cut-points for pathologic 24-
hour, postprandial and nocturnal esophageal acidity
assessed using integrated acidity and time pH < 4. For
each analysis, the area under the ROC curve was signifi-
cantly different from 0.5 (P < 0.0001). The cut-points
were based on comparisons of data from all GERD sub-
jects (n = 57) to data from all normal subjects (n = 26).
Figure 2-left illustrates that the prevalence of pathologic
postprandial esophageal reflux in the index study meas-
ured as time pH < 4 was not significantly different (P =
1.00, McNemar's Test) from that measured as integrated
acidity. Figure 2-right shows that only 4 normal values of
postprandial integrated acidity had corresponding values
of pathologic time pH < 4.
Prevalence of pathologic 24-hour esophageal acidity assessed with integrated acidity and time pH < 4 in the index study (n =  46) Figure 1
Prevalence of pathologic 24-hour esophageal acidity assessed with integrated acidity and time pH < 4 in the 
index study (n = 46). The left panel gives prevalence with the 95% confidence interval. The right panel gives values for time 
pH < 4 from records with normal integrated acidity.
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Table 1: Cut-points, Sensitivities, Specificities and ROC Areas for Pathologic Integrated Esophageal Acidity and Time Esophageal pH < 
4.
Period Integrated Acidity (mmol.hr/L) Time pH < 4(%)
24-hour (900–900)
Cut-point 8.1 4.3
Sensitivity (%) 72 89
Specificity (%) 88 81
ROC Area 0.86 [0.77,0.94] 0.90 [0.84, 0.97]
Postprandial (900–2200)
Cut-point 1.85 6.8
Sensitivity (%) 92 85
Specificity (%) 62 85
ROC Area 0.82 [0.72, 0.91] 0.88 [0.80, 0.95]
Nocturnal (2200–900)
Cut-point 1.3 2.1
Sensitivity (%) 79 81
Specificity (%) 77 85
ROC Area 0.79 [0.69, .90] 0.84 [0.74, .92]
Results are from 26 normal and 57 GERD subjects. Values in brackets for ROC area are the 95 % confidence intervals.BMC Gastroenterology 2008, 8:15 http://www.biomedcentral.com/1471-230X/8/15
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Figure 3-left illustrates that the prevalence of pathologic
Prevalence of pathologic postprandial esophageal acidity assessed with integrated acidity and time pH < 4 in the index study (n  = 46) Figure 2
Prevalence of pathologic postprandial esophageal acidity assessed with integrated acidity and time pH < 4 in 
the index study (n = 46). The left panel gives prevalence with the 95% confidence interval. The right panel gives values for 
time pH < 4 from records with normal integrated acidity.
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Prevalence of pathologic nocturnal esophageal acidity assessed with integrated acidity and time pH < 4 in the index study (n =  46) Figure 3
Prevalence of pathologic nocturnal esophageal acidity assessed with integrated acidity and time pH < 4 in the 
index study (n = 46). The left panel gives prevalence with the 95% confidence interval. The right panel gives values for time 
pH < 4 from records with normal integrated acidity.
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nocturnal esophageal reflux in the index study was signif-
icantly higher (P = 0.0003, McNemar's Test) when meas-
ured as time pH < 4 than when measured as integrated 
acidity. Figure 3-right shows that 13 normal values of inte-
grated acidity had corresponding values of pathologic
time pH < 4 as high as 14%.
Figure 4 illustrates that results from the 3rd study confirm
those from the index study. That is, the prevalence of both
pathologic 24-hour and nocturnal esophageal reflux in
the 3rd study was significantly higher (both P < 0.0001,
McNemar's Test) when measured as time pH < 4 than
when measured as integrated acidity. As was also the case
with the index study, the prevalence of pathologic post-
prandial esophageal reflux in the 3rd study measured as
time pH < 4 was not significantly different (P = 0.267,
McNemar's Test) from that measured as integrated acidity.
The specificities for the cut-points given in Table 1 are all
less than 100%; therefore, it is likely that at least some of
the values for pathologic esophageal reflux during PPI
treatment represent false-positive values. To examine this
possibility, we used Bayes' rule to calculate the probability
that the observed prevalence of pathologic esophageal
reflux in the index and 3rd studies combined is greater
than the prevalence of false-positive values. In Table 1, the
specificity using the cut-point for pathologic 24-hour inte-
grated esophageal acidity of 8.1 mmol.hr/L was 88%
because 23 of the 26 normal subjects had values for 24-
hour integrated esophageal acidity that were lower than
8,1. The 3 subjects with values above 8.1 (12%) repre-
sented false positives. In the index and 3rd study, 13% of
subjects had pathologic integrated esophageal acidity and
we used Bayes' rule to calculate the probability that this
proportion was higher than the proportion of false posi-
tives in the control group used to establish the cut-point
given in Table 1. Table 2 indicates that with 24-hour inte-
grated esophageal acidity, the probability that the preva-
lence of pathologic esophageal reflux is greater than the
corresponding prevalence of false-positive values is 0.139.
Similarly, in Table 1, the specificity using the cut-point for
pathologic time esophageal pH < 4 of 4.3% was 81%
because 21 of the 26 normal subjects studied had values
for 24-hour time esophageal pH < 4 that were lower than
4.3. The 5 subjects with values above 4.3 (19%) repre-
sented false positives. In the index and 3rd study, 47% of
subjects had pathologic time esophageal pH < 4 and Table
2 indicates that the probability that the prevalence of 24-
hour pathologic esophageal reflux is greater than the cor-
responding prevalence of false-positive values is 0.985.
Corresponding probabilities for the nocturnal period
were pathologic integrated acidity, 0.066, and time pH <
4, .999. Thus, the probability is at least 0.86 that values for
pathologic integrated esophageal acidity are false-positive
values, whereas the probability is at most only 0.015 that
values for pathologic time esophageal pH < 4 are false-
positive values.
Table 3 gives the values for the area under the receiver
operator characteristic (ROC) curves for analyses of gastric
acidity stratified in terms of pathologic esophageal acid
exposure. The area under the ROC curve is conceptually
equivalent to the Wilcoxon statistic [15-18] and is a quan-
titative measure of the extent to which integrated gastric
acidity differs between records with pathologic esopha-
geal reflux and those with normal esophageal reflux. That
is, the ROC area represents the probability that a subject
selected randomly from the pathologic reflux group will
have a higher value for gastric acidity than a subject
Prevalence of pathologic esophageal acidity assessed with integrated acidity and time pH < 4 in the 3rd study (n = 52 records) Figure 4
Prevalence of pathologic esophageal acidity assessed with integrated acidity and time pH < 4 in the 3rd study 
(n = 52 records). Data are from 24-hour esophageal recordings on the 8th day of treatment with 20 mg omeprazole or 20 mg 
rabeprazole. Vertical bars give the 95% confidence interval.
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selected randomly from the normal reflux group [15-18].
If there is no overlap in gastric acidity between the 2
groups, the area will be 1.00 and the probability will be
100%. If the distributions are identical, the area will be
0.50 and the probability will be 50%, i.e. the same as
chance alone.
In the index study, the ROC areas for integrated acidity
were all higher than 0.7, and each curve was significantly
different from 0.5. In contrast, for the data for time pH <
4, the ROC areas were all lower than 0.7, and the area for
nocturnal gastric acidity in the index study was not signif-
icantly different from 0.5 (Table 3). The overall odds of
pathologic time esophageal pH < 4 were higher than cor-
responding values for pathologic integrated esophageal
acidity over 24 hours and during the nocturnal period
(Table 3), because in GERD subjects treated with a PPI,
measuring time esophageal pH < 4 significantly overesti-
mates the prevalence of pathologic esophageal acid expo-
sure during these periods.
To attempt to confirm the results from the index study, we
conducted similar analyses of data from days 1, 2 and 8 of
PPI treatment in the 3rd study. We anticipated that we
might obtain more precise estimates of relationships
between gastric acidity and the probability of pathologic
esophageal reflux with data from the 3rd study, because
more records (156) would be analyzed and the data
would be distributed over a wider range because on days
1 and 2, treatment effects of the PPI would be submaxi-
mal. This latter phenomenon was supported by the find-
ing that the overall odds of pathologic esophageal reflux
for each period in the 3rd study were higher than corre-
sponding values from the index study (Table 3).
A major feature of analyses of results from the 3rd study is
that they confirmed corresponding results from the index
study. That is, these analyses showed that both integrated
gastric acidity and time gastric pH < 4 provide important
information regarding the probability of pathologic
esophageal reflux during the same period. One difference,
however, is that in the 3rd study, the ROC curve for time
gastric pH < 4 for the nocturnal period was significantly
different from chance alone, because the 95% confidence
interval for the ROC area does not include 0.5 (Table 3).
This finding indicates that the lack of statistical signifi-
cance for corresponding analyses from the index study
probably represents a false-negative value because of the
smaller sample size in the index study.
Table 2: Bayesian Posterior Probabilities that the Prevalence of Pathologic Esophageal Reflux During PPI Treatment is Greater than 
the Prevalence of False-Positive Values for Pathologic Integrated Esophageal Acidity and Time Esophageal pH < 4.
Probability that Observed Prevalence of Pathologic Esophageal Reflux is Greater than Prevalence of False-Positive Values
Period Integrated Esophageal Acidity Time Esophageal pH < 4
24-hour 0.139 0.985
Nocturnal 0.066 0.999
Bayesian posterior probabilities were calculated using the values for the prevalence of false-positive values given in Table 1, the combined 
prevalence of pathologic esophageal reflux calculated from the index and 3rd studies, and a flat prior probability [8]. The calculations were for 
values of prevalence from 0 to 1.0 in steps of 0.05. The flat prior probability considered all prevalence values from 0 to 1.0 to be equally probable.
Table 3: Parameter Values for the Relationship Between Measures of Gastric Acidity and the Odds Pathologic Esophageal Reflux.
Index Study (n = 46 records) 3rd Study (n = 156 records)
Period Integrated Acid (mmol.hr/L) Time pH < 4 (%) Integrated Acid (mmol.hr/L) Time pH < 4 (%)
24-hour (900–900)
ROC Area 0.77 (0.59, 0.94) 0.68 (0.52, 0.83) 0.74 (0.66, 0.82) 0.64 (0.55, 0.74)
Overall Odds Pathologic Reflux 0.18 0.77 0.37 2.52
Postprandial (900–2200)
ROC Area 0.71 (0.55, 0.88) 0.69 (0.52, 0.85) 0.80 (0.74, 0.87) 0.77 (0.70, 0.85)
Overall Odds Pathologic Reflux 0.44 0.48 1.05 1.31
Nocturnal (2200–900)
ROC Area 0.75 (0.57, 0.93) 0.62 (0.45, 0.78) 0.75 (0.67, 0.83) 0.62 (0.53, 0.71)
Overall Odds Pathologic Reflux 0.18 0.84 0.21 1.59
Parameter values were calculated from data illustrated in Figures 1–4 using values for gastric acidity stratified on the basis of pathologic esophageal 
acidity. Numbers in parentheses for ROC area give the 95% confidence interval.BMC Gastroenterology 2008, 8:15 http://www.biomedcentral.com/1471-230X/8/15
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As occurred in the index study, in the 3rd study, the ROC
areas with time pH < 4 were consistently lower than cor-
responding values with integrated acidity, and the overall
odds of pathologic esophageal reflux with time pH < 4
were consistently higher than corresponding values with
integrated acidity (Table 3).
Some have evaluated gastric pH during PPI treatment by
measuring nocturnal gastric acid breakthrough (NAB; 19–
24). Initially, NAB was arbitrarily defined as continuous
nocturnal gastric pH <4 for more than 1 hour in subjects
who received a PPI twice daily [19-21]. Subsequently,
however, NAB was defined as simply continuous noctur-
nal gastric pH <4 for more than 1 hour during PPI treat-
ment [25]. Although NAB has been claimed to increase
the risk of nocturnal esophageal acid reflux [25], none of
the published analyses have shown clearly that NAB dis-
tinguishes between normal and pathologic nocturnal
esophageal reflux during the same time and in the same
subjects in which NAB occurs. Accordingly, we examined
the extent to which NAB might be useful in predicting the
occurrence of pathologic nocturnal esophageal reflux in
GERD subjects during PPI treatment.
Table 4 indicates that in the index study, 34 of 46 subjects
(74%) had NAB. Of the subjects with NAB, only 7 (21%)
had pathologic nocturnal integrated esophageal acidity
and 18 (53%) had pathologic nocturnal time esophageal
pH < 4. In the 3rd study, 140 of 156 subjects (90%) had
NAB. Of the subjects with NAB, only 49 (35%) had path-
ologic nocturnal integrated esophageal acidity and 97
(69%) had pathologic nocturnal time esophageal pH < 4.
As mentioned previously, the higher percentages of path-
ologic esophageal acidity with time pH < 4 compared to
those with integrated acidity occur because time pH < 4
overestimates the prevalence of pathologic esophageal
acidity.
Table 4 also indicates that if NAB is absent there is a high
probability that integrated nocturnal esophageal acidity
will be normal, because of the subjects without NAB 0 of
12 subjects in the index study and 1 of 16 subjects in the
3rd study had pathologic integrated esophageal acidity.
This is not the case, however, measuring time esophageal
pH < 4.
Discussion
Previously [3], we found that the effect of rabeprazole on
esophageal acid exposure was significantly less when
measured as time pH < 4 than when measured as inte-
grated acidity. The present analyses illustrate an important
clinical consequence of this difference; namely, in asymp-
tomatic GERD subjects being treated with a PPI, 46% had
pathologic 24-hour esophageal acid exposure measured
as time pH < 4, whereas only 15% of the same records had
pathologic esophageal acid exposure measured as inte-
grated acidity. The possibility that the surprisingly high
prevalence of pathologic esophageal reflux in asympto-
matic GERD subjects during PPI treatment was an artifact
resulting from the way that the data were analyzed was
not considered by the authors of the original paper [1] or
the accompanying editorial [2].
It is important to emphasize that the major difference
between integrated acidity and time pH < 4 relates to the
prevalence of pathologic esophageal reflux. If esophageal
reflux is pathologic with time pH < 4, there is a low prob-
ability that it will also be pathologic with integrated acid-
ity. On the other hand, if esophageal acid exposure is
normal with time pH < 4, there is a high probability that
it will also be normal with integrated acidity.
Table 4: Prevalence of Pathologic Esophageal Reflux Stratified by Nocturnal Gastric Breakthrough.
Index Study
NAB (n = 34) No NAB (n = 12)
Pathologic Nocturnal Esophageal Acid Integrated Acidity Time pH < 4 Integrated Acidity Time pH < 4
YES 7 18 0 3
NO 27 16 12 9
3rd Study
NAB (n = 140) No NAB (n = 16)
Pathologic Nocturnal Esophageal Acid Integrated Acidity Time pH < 4 Integrated Acidity Time pH < 4
YES 49 97 1 9
NO 91 43 15 7BMC Gastroenterology 2008, 8:15 http://www.biomedcentral.com/1471-230X/8/15
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Our definition of pathologic esophageal reflux is based on
the value for esophageal acidity (integrated acidity or time
pH < 4) that best distinguishes between normal and
GERD subjects. Others have measured pathologic esopha-
geal reflux as those reflux episodes that are associated with
symptoms attributable to GERD [26]. This definition of
pathologic esophageal reflux may be helpful in under-
standing the pathogenesis of symptoms such as heart-
burn, but it is not useful in distinguishing between
normal and GERD subjects on the basis of esophageal
acid exposure.
The significant difference in the prevalence of pathologic
24-hour esophageal reflux measured as integrated acidity
compared to that measured as time pH < 4 was attributa-
ble to a difference between the two measures during the
nocturnal period. The prevalence of pathologic esopha-
geal reflux during the postprandial period was similar
with integrated acidity and time pH < 4. In contrast, the
prevalence of pathologic esophageal reflux during the
nocturnal period was significantly lower with integrated
acidity than with time pH < 4. This difference during the
nocturnal period is probably attributable to long periods
of esophageal pH between pH 3 and pH 4, which will give
relatively high values for time pH < 4, but relatively low
values of integrated acidity.
Another important difference between the two measures
of esophageal acidity is that with integrated acidity, the
PPI is much more effective during the nocturnal period
than during the postprandial period. In contrast, with
time pH < 4, the prevalence pathologic esophageal reflux
is similar during the nocturnal and postprandial periods.
This difference with integrated acidity is consistent with
the findings in GERD subjects with esophagitis who are
treated with a PPI that esophagitis heals in approximately
90%, while heartburn resolves in only 60–70% [27]. It
seems likely that abolishing pathologic nocturnal esopha-
geal acid is important in healing esophagitis, whereas
abolishing pathologic postprandial esophageal acid is
important in resolving heartburn. Measuring time
esophageal pH < 4 cannot account for these findings in
GERD subjects with esophagitis.
All of the major findings from analyses of the index study
were replicated in analyses of the 3rd study. This confir-
mation indicates that the findings in the index study
reflect reproducible differences between integrated
esophageal acidity and time esophageal pH < 4 in GERD
subjects treated with a PPI, and do not result from unrec-
ognized peculiarities related to the conduct of the index
study.
The results from the present analyses of esophageal pH
from GERD subjects may also be applicable to subjects
with Barrett's esophagus, who are believed to be relatively
resistant to PPI treatment [28-30]. A substantial portion of
subjects with Barrett's esophagus have been found to have
pathologic esophageal acid exposure even when treated
with high doses of a PPI. In all instances, however,
esophageal acid exposure has been measured as time
esophageal pH < 4 [17-19], and as shown in the present
analyses, this measurement leads to artifactually high esti-
mates of the prevalence of pathologic esophageal reflux.
From the clinical standpoint, our present findings only
affect the interpretation of measurements of 24-hour
esophageal pH; they do not influence the indications for,
such measurements. For example, if a clinician records
esophageal pH in a patient with GERD to assess the effect
of a PPI on esophageal acid exposure, integrated esopha-
geal acidity should be calculated instead of time esopha-
geal pH < 4, because this will reduce the possibility of
reaching a false conclusion that esophageal acid exposure
is abnormally high.
Our present analyses also indicate that NAB [19-25] is not
a useful indicator of the probability of pathologic noctur-
nal esophageal reflux. Using integrated esophageal acid-
ity, most subjects with NAB did not have pathologic
esophageal reflux. On the other hand, although the
absence of NAB was infrequent in GERD subjects during
treatment with a PPI, when NAB was absent, it was a use-
ful predictor of normal nocturnal integrated esophageal
acidity. Using time esophageal pH < 4, both the presence
and absence of NAB were associated with higher probabil-
ities of pathologic esophageal reflux.
Our conclusion that NAB is not a useful predictor of path-
ologic esophageal reflux agrees with the conclusion from
a previous study that measured gastric and esophageal pH
in normal and GERD subjects at baseline and during PPI
treatment [24]. Although this previous study did not
relate NAB to nocturnal esophageal pH measured at the
same time, the data provided appear to indicate that for
NAB in GERD subjects during PPI treatment, its positive
predictive value was low and its negative predictive value
high.
One limitation that applies to analyses of gastric pH
recordings in general, is that they do not consider the
effect of the PPI on gastric volume. This is potentially
important because the effect of a PPI during fasting is pri-
marily on gastric volume with only a small change in gas-
tric pH [31,32]. This phenomenon would result in
prevention of pathologic nocturnal esophageal reflux by a
relatively small decrease in gastric acidity accompanied by
a decrease in intragastric volume. Even with this caveat,
however, measuring gastric acidity during the nocturnalBMC Gastroenterology 2008, 8:15 http://www.biomedcentral.com/1471-230X/8/15
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period still provides important information regarding the
likelihood of pathologic nocturnal esophageal reflux.
Conclusion
In GERD subjects treated with a PPI, measuring time
esophageal pH < 4 will significantly overestimate the
prevalence of pathologic esophageal acid exposure over
24 hours and during the nocturnal period.
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